The Impact of Blood Pressure and Baroreflex Sensitivity on Wind-Up : Anesthesia & Analgesia

Secondary Logo

Journal Logo

Analgesia: Research Report

The Impact of Blood Pressure and Baroreflex Sensitivity on Wind-Up

Chung, Ok Yung MD, MBA; Bruehl, Stephen PhD

Author Information
Anesthesia & Analgesia 107(3):p 1018-1025, September 2008. | DOI: 10.1213/ane.0b013e31817f8dfe
  • Free

Injury to tissues and peripheral nerves can result in enhanced responsiveness to pain transmission, depressed inhibition, and eventual amplification of pain due to peripheral and central sensitization.1,2 Wind-up is a frequency-dependent increase in the excitability of spinal cord neurons that is evoked by afferent C-fiber stimulation.3 This phenomenon may underlie the continuation of pain sensation with prolonged or repetitive stimuli. Wind-up can be used as an investigative tool for central sensitization.3 Chronic pain patients exhibit greater wind-up than do pain-free controls.4

Previous work has documented functional interactions between the cardiovascular and pain regulatory systems.5 Studies indicate that elevated resting blood pressure (BP),6–8 baroreceptor stimulation,9 and elevated spontaneous baroreflex sensitivity (BRS)10 all are associated with diminished responsiveness to acute pain stimuli in healthy individuals. Antinociception related to elevated BP may be mediated by a circuit involving baroreceptors, the nucleus tractus solitarius, the paraventricular hypothalamus, and the rostroventromedial medulla (RVM), which sends projections to the spinal cord via the dorsolateral funiculus.11,12 This descending pain inhibition reduces pain transmission at the dorsal horn. If the critical frequency of C-fiber activation is not achieved, wind-up may not be induced. One aim of this study was to examine whether elevated BP and BRS are associated with reduced wind-up in healthy individuals.

The extent to which this hypothesized inverse relationship between wind-up and both resting BP and BRS might be affected by chronic pain is unknown. Chronic pain depends on the convergence of central descending modulation, spinal neuronal plasticity, and primary afferent drive.13 Persistent afferent input from injured peripheral nerves can produce neuroplastic changes in the RVM which results in descending facilitation of spinal nociceptive input.14 If sufficient temporal summation and recruitment of C-fibers occur as a consequence of enhanced spinal sensitivity, wind-up can be triggered.

Elevations in BP stimulate the baroreflex: baroreceptor output travels to the nucleus tractus solitarius and stimulates descending nociceptive inhibition.12 BRS is diminished during periods of stress and pain.10,15,16 Reduced BRS would reduce this baroreflex-dampening of pain. A net descending pain facilitation arising from the RVM, related in part to altered BRS,17 would further enhance afferent noxious input to the spinal cord and wind-up.14,18 Chronic pain might therefore be expected to alter associations between wind-up and both BP and BRS. Prior work indicates that hypoalgesia related to BP and BRS is significantly altered by chronic pain.19–21

A final aim of this study was to address potential modulators of wind-up. Animal studies suggests that wind-up can be modulated by both spinal and supraspinal sites of opioid and noradrenergic action.22–26 Impaired α-2 adrenergic inhibitory activity (ADRA2) could increase wind-up in chronic pain.22 A final aim of this study was therefore to examine whether endogenous ADRA2 mechanisms modulate wind-up in humans, and explore the degree to which ADRA2 changes associated with chronic pain contribute to any alterations in the relationships between BP, BRS, and wind-up.

In summary, this study tested: 1) whether higher resting BP and greater spontaneous BRS were associated with lower wind-up in healthy controls, 2) whether these associations are altered in chronic pain patients, and 3) the extent to which ADRA2 mechanisms contribute to these relationships.



This study used a randomized, double-blind, placebo-controlled crossover design with administration of yohimbine, a selective ADRA2 receptor antagonist.


The sample consisted of 30 healthy pain-free controls and 26 individuals with chronic low back pain (LBP) recruited through online advertisements. Inclusion criteria were: age between 18 and 55 yr; current normotensive status; no history of cardiovascular disease, hypertension, liver or kidney disorders, or opiate dependence; no current daily use of opioid analgesics, and no current use of anti-hypertensive, opioid analgesic, or antidepressant medications. All subjects were free of current major depression, panic disorder, or posttraumatic stress disorder based on results of a structured clinical interview (Structured Clinical Interview for DSM-IV Axis I Disorders; 27). Potential subjects who were pregnant were excluded and all participants were asked to refrain from use of analgesics, nonsteroidal anti-inflammatory drugs, or any medications potentially affecting BP for 12 h prior to and avoid caffeine 3 h prior to study participation. Additional inclusion criteria for LBP subjects were persistent LBP of at least 3 mo duration and a typical daily pain intensity of at least 3/10 (0 = “No Pain” and 10 = “Worst Pain Possible”). Subject characteristics are summarized in Table 1.

Table 1:
Subject Characteristics

Study Drug

The study drug was yohimbine hydrochloride, a selective pharmacological antagonist of ADRA2 receptors.28 Yohimbine produces effective ADRA2 receptor blockade within 15–30 min after onset of infusion.28,29 Yohimbine was compounded by the Vanderbilt Investigational Pharmacy (source: Professional Compounding Centers of America, Houston, TX) and administered (0.4 mg/kg) under an Investigational New Drug protocol filed with the Food and Drug Administration. Saline placebo was dispensed from Vanderbilt Investigational Pharmacy stock (Food and Drug Administration approved).

Assessment of Spontaneous BRS

The sequence technique was used to assess spontaneous BRS in the time domain.30 This technique identifies spontaneous ramps in BP (progressive increases or decreases in BP) that are associated with concordant changes in R-R interval. BRS was indexed in this study through simultaneous assessment of continuous beat-to-beat R-R interval via 5-lead electrocardiogram and noninvasive beat-to-beat BP assessment using a Portapres (Finapres Medical Systems BV, Amsterdam, The Netherlands) placed on the middle finger of the non-dominant hand. Output was recorded by the WINDAQ data acquisition system (DI220, DATAQ, Akron, OH, 14 Bit, 500 Hz), visually inspected for artifacts, and processed off-line using software custom written in PV-Wave language (PV-wave, Visual Numerics Inc., Houston, TX). To derive the BRS values, slopes of the linear regression lines between each systolic BP (SBP) value and subsequent R-R interval values were calculated. Analyzable sequences were considered to be those with at least three intervals, and displaying correlation coefficients of r > 0.85, with BRS values calculated as the mean value of the significant slopes obtained. This custom software and BRS assessment technique have been used in several previous studies (e.g., 30).


All procedures were performed at the Vanderbilt University General Clinical Research Center and were approved by the university IRB. All subjects provided informed consent before participation. All subjects participated in two laboratory sessions 1 wk apart, at the same time of day to control for circadian rhythms. Subjects remained seated upright in a comfortable chair throughout all laboratory procedures.

During each laboratory session, subjects initially completed a 10-min seated rest period, followed by a 5-min pre-drug resting BRS assessment period (as above). A research nurse under physician supervision then placed an indwelling venous cannula in the participant's dominant arm, followed by a 25-min adaptation period during which subjects rested quietly. A 10 mL dose of normal saline (placebo) or a 0.4 mg/kg dose of yohimbine hydrochloride (in 10 mL saline vehicle) was then infused over a 10-min period using an automated infusion pump.

After a 20-min rest following drug infusion to allow peak ADRA2 antagonist activity of yohimbine to be achieved, subjects participated sequentially in a 1-min pressure pain task using a Forgione-Barber finger pressure stimulator,31 a forearm ischemic pain task,32 and thermal pain threshold and tolerance trials using the thermal stimulation device described below. Full results for these non-wind-up stimuli are detailed elsewhere.10,20

All subjects next participated in a thermal pain task using a Medoc Thermal Sensory Analyzer (TSA-II, Medoc, Inc., Ramat, Israel). This computer-controlled device was used to apply a controlled heat stimulus to the nondominant ventral forearm using a 30 × 30 mm Peltier thermistor probe as reported in prior studies (e.g., 33). Before wind-up assessment, a series of four pain threshold and four pain tolerance trials were conducted with results for the three most reliable trials within each series retained for analyses.20 Subjects then participated in a series of wind-up assessment trials using commercially available software (TPS-CoVAS v3.19, Medoc Inc.) that administered a standardized oscillating thermal stimulation protocol designed specifically to assess C-fiber-mediated temporal summation. This protocol is based on that which has been used to assess temporal summation in several previous studies (e.g., 7).

During wind-up assessment, three sequences of 10 heat pulses each were applied to the dominant ventral forearm, with the thermode in a fixed position throughout each sequence. The thermode was moved to a different non-overlapping site in the same area for each subsequent sequence of trials, with a 2-min interval between sequences. Within each pulse sequence, 10 successive pulses (0.5 s duration) were administered from a baseline temperature of 40°C at a frequency of 0.5 Hz, a frequency known to elicit C-fiber mediated wind-up in the dorsal horn.2 Three sequences with different target temperatures were conducted (47°C, 49°C, and 50°C in randomized order). At the peak of every heat pulse within each sequence, subjects were asked to provide a verbal numeric pain intensity rating using a 0–100 scale with which they had previously been familiarized (anchored with 0 = “No Pain or Warmth” and 100 = “Worst Possible Pain”). Because wind-up by definition is evidenced by increasing perceived pain intensity during repeated brief stimuli at a constant intensity (reflecting temporal summation), the slope of the line fitted to the series of 10 stimuli at each temperature was an optimal index of wind-up (Fig. 1 shows an example of placebo condition wind-up results in one healthy control and one LBP subject at 49°C). To derive such a measure for use in primary analyses, within-subject regressions were conducted regressing the series of 10 pain ratings during each wind-up trial on a dummy coded variable with a fixed interval of one (range = 1–10). This produced a standardized slope (β) for each individual at each temperature reflecting degree of wind-up. These standardized slopes were used as the dependent variables in primary analyses described below.

Figure 1.:
Placebo condition wind-up data for one healthy control subject and one low back pain (0 subject over 10 trials with constant stimulus intensity of 49°C.

Statistical Analysis

All analyses were conducted using the SPSS for Windows Version 13 statistical package (SPSS, Inc., Chicago, IL). To reduce the number of analyses and minimize possible family-wise error rate issues, analyses were restricted to resting SBP and BRS data derived for sequences in which SBP was increasing given that the literature indicates that resting SBP and increases in SBP have stronger effects on pain responses than do comparable diastolic measures.5,12 Primary analyses used a series of univariate General Linear Model (GLM) analyses to examine the main and interactive effects of resting BRS or SBP, subject type, and the study drug on the wind-up measures. Each analysis included resting pre-drug BRS or SBP (using the appropriate baseline for each drug condition), Subject type, and drug condition, and the two- and three-way interactions of these variables as the independent measures, with the dependent measure being the standardized slope of pain ratings during wind-up evaluation at each temperature. To control for the within-subject nature of the drug manipulation, a dummy coded subject ID variable was included as a control variable. Preliminary analyses indicated that drug order was significantly (P < 0.05) associated with magnitude of the effects of yohimbine on wind-up and therefore was included as a covariate in the primary analyses.

Significant interaction effects were followed-up with post hoc simple effects tests (i.e., GLM analyses within each subject type) to determine whether the individual effects contributing to the interaction were themselves significant. For the purpose of graphically portraying the source of significant interaction effects, median splits were conducted on mean baseline SBP and BRS variables and these were used to generate estimated marginal means in order to portray wind-up slopes by relatively higher and lower BRS (Mean BRS: High = 17.0 ± 1.04 ms/mm Hg, Low = 7.0 ± 0.49 ms/mm Hg) and SBP (Mean SBP: High = 112.6 ± 1.07 mm Hg, Low = 97.0 ± 1.17 mm Hg). These dichotomized cardiovascular variables were used solely for graphical presentations and were not used in primary analyses. BRS data were unavailable for nine subjects due to inability to detect a signal sufficient for reliable sequence analysis. All probability values reported are two-tailed with a P < 0.05 criterion for significance.


Preliminary Analyses

Table 2 summarizes results for placebo and yohimbine condition wind-up assessment by subject type. In the placebo condition, the LBP group displayed significantly larger wind-up slopes at all three target temperatures. These larger positive slopes indicate greater temporal summation of pain in subjects with chronic pain than in pain-free subjects. In the yohimbine condition, differences like those above were significant only for wind-up at 49°C.

Table 2:
Mean (±se) Wind-Up Slopes Across Drug Conditions and Subject Types

Preliminary GLM analyses were also conducted to examine the relationship between resting SBP and resting BRS across subject types. These analyses indicated that SBP and BRS were significantly associated in the LBP group [F(1,38) = 5.52, P < 0.05] but not in controls (P > 0.10). This former association reflected diminished BRS in LBP subjects with higher BP (r = −0.36). This difference across groups approached significance [Subject Type X SBP interaction on BRS levels: F(1, 81) = 2.78, P < 0.10].

GLM analyses were also conducted to examine the degree to which wind-up was associated with measures of thermal pain threshold and tolerance. Main effects (across subject types and drug conditions) for wind-up slope at 47°C indicated that degree of wind-up significantly predicted both thermal pain threshold [F(1,98) = 11.31, P < 0.001] and thermal pain tolerance [F (1,98) = 7.38, P < 0.01]. Follow-up correlational analyses indicated that greater wind-up at 47°C was associated with both lower pain threshold (r = −0.31) and lower pain tolerance (r = −0.34). No other significant main or interaction effects were noted (P > 0.10). Similar analyses for wind-up at 49°C and 50°C revealed no significant effects (P > 0.10).

Associations Between Resting SBP and Wind-Up

A significant subject type X SBP interaction was found for wind-up slope at 47°C [F(1,98) = 4.81, P < 0.05]. This interaction is portrayed in Figure 2. Follow-up simple effects analyses indicated that higher resting SBP levels were associated with significantly lower wind-up in healthy controls [F(1,53) = 4.91, P < 0.05], but with significantly higher wind-up in LBP subjects [F(1,43) = 4.34, P < 0.05]. Other main and interaction effects in this analysis were nonsignificant (P > 0.10).

Figure 2.:
Thermal wind-up at 47°C by resting systolic blood pressure level and subject type.

SBP analyses for wind-up slope at 49°C indicated a significant main effect of SBP [F(1,99) = 3.90, P < 0.05]. Examination of mean wind-up by relatively higher and lower SBP groups indicated that across subject types and drug conditions, individuals with higher resting SBP showed less wind-up (0.69 ± 0.05) than individuals with lower resting SBP (0.80 ± 0.05). Other main and interaction effects in this analysis were nonsignificant (P > 0.10), as were all effects in wind-up analyses at 50°C (P > 0.05).

Associations Between Resting BRS and Wind-Up

The relationship between spontaneous resting BRS and degree of wind-up was also examined. A significant subject type X BRS interaction was found for wind-up slope at 49°C [F(1,81) = 5.21, P < 0.05]. The source of this interaction is presented in Figure 3. Follow-up simple effects analyses indicated that greater spontaneous BRS was associated with significantly lower wind-up in healthy controls [F(1,42) = 10.16, P < 0.01], but BRS was not associated significantly with wind-up in LBP subjects (P > 0.10). Other main and interaction effects in this analysis were nonsignificant (P > 0.10). Similar BRS analyses for wind-up at 47°C and 50°C revealed no significant effects (P > 0.10).

Figure 3.:
Thermal wind-up at 49°C by spontaneous baroreflex sensitivity and subject type.


Our results indicated that in healthy controls, higher resting SBP and greater BRS were associated with significantly lower thermal wind-up. These findings suggest that the hypoalgesia associated with elevated BP and baroreflex activation described previously6–10 may arise, not only from greater activation of descending pain inhibitory pathways, but also from diminished activation of pain facilitatory pathways and lower central hyperexcitability.

These findings are not surprising in light of known functional links between brain structures contributing to both pain modulation and autonomic control. Key areas in the midbrain and the brainstem, such as the periaqueductal gray and the RVM allow bidirectional modulation of spinal cord activity through descending pain inhibitory and facilitatory networks.23,24 The RVM may serve a protective role by increasing its inhibitory output or conversely, become maladaptive and permit long-lasting abnormal pain. The RVM is involved in the maintenance of tactile and thermal hypersensitivity, as observed in central sensitization,23 and plays a pivotal role in the baroreflex.34 Given overlapping physiological substrates, associations between cardiovascular variables and central sensitization (reflected in wind-up) are not surprising.

We further investigated whether the presence of chronic pain altered the inverse associations between cardiovascular measures and wind-up present in healthy subjects. Our findings indicated that in contrast to the significant inverse association between resting BP and wind-up in controls, chronic pain subjects displayed a significant positive association. Chronic pain appeared to affect associations with baroreflex measures similarly. A significant inverse relationship between spontaneous BRS and wind-up observed in pain-free controls was entirely absent in the chronic pain group. These findings parallel reported alterations in BP- and BRS-related hypoalgesia in chronic pain.10,19–21 Mechanisms underlying observed changes in associations between cardiovascular variables and wind-up remain speculative. Tissue injury leading to persistent afferent input induces peripheral and central sensitization. The increased neuronal barrage at the spinal level activates spinal projection neurons and can lead to descending supraspinal facilitation in part via the RVM, which in turn plays a role in cardiovascular regulation.34 Findings of impaired BRS in chronic pain patients10,16 could further augment abnormal pain as a result of reduced baroreceptor-mediated analgesia.

Our results demonstrated that higher SBP was associated with lower BRS only in chronic pain subjects. These findings may have important prognostic implications for the pathogenesis of cardiovascular disease in individuals suffering from chronic pain who have increased hypertension risk, as prior work suggests.35 Individual differences in baroreflex-mediated hypoalgesia predict subsequent increases in resting BP.36 Depressed baroreflex function has been associated with increased cardiovascular morbidity,37–39 including pathogenesis of hypertension.40 Our results suggest that resting BP in chronic pain patients is increased to the extent that central sensitization processes are activated, whether this relationship is causal is yet to be determined. A genetically determined mechanism that leads to reduced BRS may also put a subgroup of chronic pain individuals at higher risk for cardiovascular disease, hypertension and end-organ damage depending upon their level of baroreflex and autonomic balance.37,41–43 Acute musculoskeletal injury results in a shift in the autonomic nervous system toward a sympathetic dominance and significantly lower BRS,44–46 and such findings may be relevant to long-term hypertension risk in chronic pain as well.40

A final aim of this study was to test for noradrenergic modulation of wind-up and its contribution to associations with cardiovascular function. Both opioidergic and noradrenergic neurons have been shown to modulate C-fiber central hyperexcitability22 and to have analgesic synergy.47,48 Moreover, both neurotransmitter systems are involved in cardiovascular regulation.5 In this study, we specifically tested the possible influence of ADRA2 mechanisms (which impact both pain and cardiovascular systems) on human wind-up. Yohimbine, an ADRA2 antagonist, did not alter wind-up in this study, nor did it contribute to the observed links between cardiovascular measures and wind-up. The expected increase in wind-up with yohimbine in the chronic pain group may not have occurred because of selective drug effects on the C-fiber-mediated input, rather than directly on the process of wind-up. Yohimbine could have exerted antinociception through serotonin1A receptors such that no change in wind-up was perceived.49

The following study limitations are acknowledged. Relationships between cardiovascular measures and wind-up were observed at 47°C and 49°C, but not at 50°C. The neural processes that contribute to wind-up might evoke such profound neural discharges to the initial heat pulse at this latter target temperature that additional increases in neural discharges evoked by subsequent heat stimuli were difficult to achieve. That is, this higher temperature may have elicited a stronger wind-up response in all subjects, even those with relatively little central sensitization, which may have reduced wind-up variability. Another limitation is sample size and, therefore, statistical power issues may have contributed to some of the nonsignificant findings. Power issues could also have contributed to the lack of ADRA2 blockade effects, whereas examination of observed effect sizes suggest this is unlikely. A related issue is that blood levels of yohimbine and its metabolites were not obtained. Therefore, the degree of ADRA2 blockade at the time of wind-up testing could not be confirmed, whereas yohimbine's primary metabolite exhibits significant ADRA2 blockade actions with a 5 h half-life.28 Finally, the issue of elevated Type I error rate due to multiple statistical tests must be considered. Although the number of primary analyses was not large (six), use of the bonferroni correction would have eliminated significant study findings. Although the bonferroni correction is considered by some to be overly conservative and may substantially inflate the risk of Type II error,50,51 conclusions drawn from the current findings would clearly be strengthened by replication.

In summary, elevated resting BP and greater spontaneous BRS inhibit wind-up (an index of central pain sensitization) in healthy individuals, but not in individuals with chronic pain. The absence or reversal of normal interactions between overlapping systems modulating cardiovascular function and pain may contribute to impaired cardiovascular regulation and increased hypertension and cardiovascular risk in chronic pain patients.


1. Ji RR, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001;8:1–10
2. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. Pain 1999;79:75–82
3. Herrero JF, Laird JM, López-García JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol 2000;61:169–203
4. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001;91:165–75
5. Bruehl S, Chung OY. Interactions between the cardiovascular and pain regulatory systems: an updated review of mechanisms and possible alterations in chronic pain. Neurosci Biobehav Rev 2004;28:395–414
6. Bruehl S, Carlson CR, McCubbin JA. The relationship between pain sensitivity and blood pressure in normotensives. Pain 1992;48:463–7
7. Fillingim R, Maixner W, Kincaid S, Silva S. Sex differences in temporal summation but not sensory-discriminative processing of thermal pain. Pain 1998;75:121–7
8. Fillingim RB, Maixner W. The influence of resting blood pressure and gender on pain responses. Psychosom Med 1996;58: 326–32
9. Rau H, Elbert T. Psychophysiology of arterial baroreceptors and the etiology of hypertension. Biol Psychol 2001;57:179–201
10. Chung OY, Bruehl S, Diedrich L, Diedrich A, Chont M, Robertson D. Baroreflex sensitivity associated hypoalgesia in healthy states is altered by chronic pain. Pain 2007 Dec 28 [Epub ahead of print]
11. Watkins LR, Thurston CL, Fleshner M. Phenylephrine-induced antinociception: investigations of potential neural and endocrine bases. Brain Res 1990;528:273–84
12. Edwards L, Ring C, McIntyre D, Carroll D. Modulation of the human nociceptive flexion reflex across the cardiac cycle. Psychophysiology 2001;38:712–18
13. Gardell LR, Vanderah TW, Gardell SE, Wang R, Ossipov MH, Lai J, Porreca F. Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J Neurosci 2003;23:8370–9
14. Burgess SE, Gardell LR, Ossipov MH, Malan TP Jr, Vanderah TW, Lai J, Porreca F. Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci 2002;22:5129–36
15. Steptoe A, Sawada Y. Assessment of baroreflex function during mental stress and relaxation. Psychophysiology 1989;26:140–7
16. Furlan R, Colombo S, Perego F, Atzeni F, Diana A, Barbic F, Porta A, Pace F, Malliani A, Sarzi-Puttini P. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol 2005;32: 1787–93
17. Jin Y, Sato J, Yamazaki M, Omura S, Funakubo M, Senoo S, Aoyama M, Mizumura K. Changes in cardiovascular parameters and plasma norepinephrine level in rats after chronic constriction injury on the sciatic nerve. Pain 2008; 135:221–31
18. Furst S. Transmitters involved in antinociception in the spinal cord. Brain Res Bull 1999;48:129–41
19. Bruehl S, Chung OY, Ward P, Johnson B, McCubbin JA. The relationship between resting blood pressure and acute pain sensitivity in healthy normotensives and chronic back pain sufferers: the effects of opioid blockade. Pain 2002;100:191–201
20. Bruehl S, Chung OY, Diedrich L, Diedrich A, Robertson D. The relationship between resting blood pressure and acute pain sensitivity: effects of chronic pain and alpha-2 adrenergic blockade. J Behav Med 2008;31:71–80
21. Maixner W, Fillingim R, Kincaid S, Sigurdsson A, Harris MB. Relationship between pain sensitivity and resting arterial blood pressure in patients with painful temporomandibular disorders. Psychosom Med 1997;59:503–11
22. Yaksh TL, Hua XY, Kalcheva I, Nozaki-Taguchi N, Marsala M. The spinal biology in humans and animals of pain states generated by persistent small afferent input. Proc Natl Acad Sci USA 1999;96:7680–6
23. Pertovaara A. A neuronal correlate of secondary hyperalgesia in the rat spinal dorsal horn is submodality selective and facilitated by supraspinal influence. Exp Neurol 1998;149:193–202
24. Pertovaara A, Kontinen VK, Kalso EA. Chronic spinal nerve ligation induces changes in response characteristics of nociceptive spinal dorsal horn neurons and in their descending regulation originating in the periaqueductal gray in the rat. Exp Neurol 1997;147:428–36
25. Pertovaara A, Wei H. Dual influence of the striatum on neuropathic hypersensitivity. Pain 2008;137:50–9
26. Pertovaara A, Wei H. A dissociative change in the efficacy of supraspinal versus spinal morphine in the neuropathic rat. Pain 2003;101:237–50
27. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: Am Psychiatric Press, Inc., 1997
    28. Le Corre P, Dollo G, Chevanne F, Le verge R. Biopharmaceutics and metabolism of yohimbine in humans. Eur J Pharm Sci 1999;9:79–84
    29. Goldstein DS, Golczynska A, Stuhlmuller J, Holmes C, Rea RF, Grossman E, Lenders J. A test of the “epinephrine hypothesis” in humans. Hypertension 1999;33:36–43
    30. Tank J, Jordan J, Diedrich A, Stoffels M, Franke G, Faulhaber HD, Luft FC, Busjahn A. Genetic influences on baroreflex function in normal twins. Hypertension 2001;37:907–10
    31. Forgione AG, Barber TX. A strain gauge pain stimulator. Psychophysiology 1971;8:102–6
    32. Maurset A, Skoglung LA, Hustveit O, Klepstad P, Oye I. A new version of the ischemic tourniquet pain test. Methods Find Exp Clin Pharmacol 1992;13:643–7
    33. Fillingim RB, Edwards RR. Is self-reported childhood abuse history associated with pain perception among healthy young men and women? Clin J Pain 2005;21:387–97
    34. Minson JB, Llewellyn-Smith IJ, Arnolda LF, Pilowsky PM, Oliver JR, Chalmers JP. Disinhibition of the rostral ventral medulla increases blood pressure and Fos expression in bulbospinal neurons. Brain Res 1994;646:44–52
    35. Bruehl S, Chung OY, Jirjis JN, Biridepalli S. Prevalence of clinical hypertension in chronic pain patients compared to non-pain general medical patients. Clin J Pain 2005;21:147–53
    36. Brody S, Rau H. Behavioral and psychophysiological predictors of self-monitored 19-month blood pressure change in normotensives. J Psychosom Res 1994;38:885–91
    37. Sleight P. The importance of the autonomic nervous system in health and disease. Aust N Z J Med 1997;27:467–73
    38. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, Nohara R, Bigger JT Jr, Camm AJ, Schwartz PJ; ATRAMI Investigators. Autonomic tone and reflexes after myocardial infarction. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001;103:2072–7
    39. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) investigators. Lancet 1998;351:478–84
    40. Ducher M, Fauvel JP, Cerutti C. Risk profile in hypertension genesis: a five-year follow-up study. Am J Hypertens 2006;19: 775–80
    41. Shan ZZ, Dai SM, Su DF. Arterial baroreflex deficit induced organ damage in sinoaortic denervated rats. J Cardiovasc Pharmacol 2001;38:427–37
    42. Andresen MC, Brown AM. Baroreceptor function in spontaneously hypertensive rats. Effect of preventing hypertension. Circ Res 1980;47:829–34
    43. Struyker-Boudier HA, Evenwel RT, Smits JF, Van Essen H. Baroreflex sensitivity during The development of spontaneous hypertension in rats. Clin Sci (Lond) 1982;62:589–94
    44. Grimm DR, Cunningham BM, Burke JR. Autonomic nervous system function among individuals with acute musculoskeletal injury. J Manipulative Physiol Ther 2005;28:44–51
    45. Janig W. The sympathetic nervous system in pain. Eur J Anaesthesiol Suppl 1995;10:53–60
    46. Koltzenburg M, McMahon SB. The enigmatic role of the sympathetic nervous system in chronic pain. Trends Pharmacol Sci 1991;12:399–402
    47. Sullivan AF, Dashwood MR, Dickenson AH. Alpha2-adrenoreceptor modulation of nociception in rat spinal cord: location, effects and interactions with morphine. Eur J Pharmacol 1987;138:169–77
    48. Stone LS, MacMillan LB, Kitto KF, Limbird LE, Wilcox GL. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci 1997;17:7157–65
    49. Shannon HE, Lutz EA. Yohimbine produces antinociception in the formalin test in rats: involvement of serotonin (1A) receptors. Psychopharmacology (Berl) 2000;149:93–7
    50. Schmidt FL. What do data really mean: research findings, meta-analysis, and cumulative knowledge in psychology. Am Psychol 1992;47:1173–81
    51. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236–8
    © 2008 International Anesthesia Research Society